TCR Affinity Enhancing Specific T cell Therapy

N/A

Report date: 2024/12/05 16:38:02

Base Information

Drug NameTCR Affinity Enhancing Specific T cell Therapy
Drug Alias NameNY-ESO-1-specific TCR affinity enhancing specific T cell therapyNY-ESO-1 TCR (Guangzhou Institute of Respiratory Disease/Guangzhou Xiangxue Pharmaceuticals)NY-ESO-1-transduced T-cells - Guangzhou- PharmaceuticalAnti-NY-ESO-1 TCR transduced T cellsTAEST-16001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Institute Of Respiratory HealthGuangzhou Xiangxue Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Institute Of Respiratory HealthSun Yat-Sen UniversityXiangxue Life Science Technology (Guangdong) Co Ltd +[5] 
Inactive CompaniesXiangxue Life Science Research CenterXiangxue Pharmaceutical
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[5] 
Inactive IndicationsUrinary Bladder NeoplasmsThyroid NeoplasmsOvarian Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A